"The whole purpose is to start to understand the disease better," he said. "The more we understand these diseases, the more proficient we will be developing new treatments." Grozdanic says the evidence shows that approximately 2,000 cases of SARDS occur every year. Some of those cases may now be identified as IMR, and treated differently. Treatment for IMR can have a relatively high success rate. "In approximately 60 percent of the Immune-Mediated Retinopathy cases, we have been able to treat it," he said. "In some cases very successfully, in some cases moderately successfully." Since IMR has only recently been identified, there are no statistics on how many dogs this disease affects. Grozdanic has also developed a test to differentiate the two types of retinopathy. Grozdanic shines colored lights in the dog's eyes to see if the pupils constrict. If the pupils constrict poorly while the doctor uses the red light, and have normal constriction when blue light is used, the patient most likely suffers from IMR. If the eyes respond to blue lights, but not red lights, then the diagnosis is SARDS. Tests show SARDS-affected eyes have almost no electrical activity. IMR-affected eyes have some electrical activity, and the retinal cells are not destroyed but have only lost function. These are the retinal cells that Grozdanic thinks can function again now that the origin of the problem is known. In his work with canine patients with IMR during the past few years, Grozdanic has restored sight in several dogs.
Science Daily
March 17, 2008
Original web page at Science Daily



